Lupin launches patient support program ‘Humrahi‘ for diabetes management

India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045

AstraZeneca Pharma India gets permission to import Palivizumab solution for injection

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus

Zydus announces IND clearance of a novel Anti-PCSK9 candidate

Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity

Lupin's Joint Airways Initiative surpasses 10,000 patients

Briefs: Mankind Pharma and Sequent Scientific

Mankind Pharma commences the commercial operations newly set-up plant in Udaipur

Lupin acquires five brands from Menarini

Lupin has been exclusively marketing these brands in the Indian market since July 2021

Bajaj Healthcare announces receipt of EIR from USFDA

The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations

Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL

Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients

Jeet will be a trusted partner in cardiovascular care